Darolutamide Takes Root With New Prostate Cancer Benchmark
Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.
Related Articles
PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC
Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.
Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care
Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.
Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’
Reshma Mahtani, DO, highlights her experience as a leader in oncology and emphasizes the need to further uplift other women in the field.
Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025
Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
CHMP Recommends EU Approval of Zanidatamab for HER2+ Advanced Biliary Tract Cancer
The EMA’s CHMP issued a positive opinion for zanidatamab in previously treated HER2-positive biliary tract cancer.
Dr LeVee on Ongoing Research With Immunotherapy and ADCs in TNBC
Alexis LeVee, MD, discusses ongoing trials investigating immunotherapy agents and antibody-drug conjugates that may challenge the current SOC for TNBC.
Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer
No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.
Dr Grisham on the FDA Approval of Avutometinib/Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer
Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.
TAR-200 Yields Prolonged DFS in BCG-Unresponsive, Papillary High-Risk NMIBC
TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.
Sasanlimab Plus BCG Improves EFS in High-Risk NMIBC
Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.